GSK1838705A is a small molecule inhibitor of the phosphoinositide 3-kinase (PI3K) pathway. It is currently being studied as a potential treatment for various types of cancers, including solid tumors and lymphomas. GSK1838705A was first developed by GlaxoSmithKline and has undergone several clinical trials.
The chemical name of GSK1838705A is 4-((4-(morpholinomethyl)-1H-pyrazol-3-yl)amino)-6-(3-methoxyphenyl)-3-(4-methyl-1H-pyrazol-3-yl)pyridine-2-carbonitrile.
The molecular formula of GSK1838705A is C25H26N8O2.
The formula weight of GSK1838705A is 462.53 g/mol.
The CAS number of GSK1838705A is 1116235-97-2.
Top Ten Keywords from Google and Synonyms
Synonyms: GSK-605, GSK605, 4-((4-(Morpholinomethyl)-1H-pyrazol-3-yl)amino)-6-(3-methoxyphenyl)-3-(4-methyl-1H-pyrazol-3-yl)pyridine-2-carbonitrile
Health Benefits of GSK1838705A
GSK1838705A has shown promising results in treating various types of cancers, particularly solid tumors and lymphomas. By inhibiting the PI3K pathway, it works to slow or stop the growth and spread of cancer cells.
Clinical studies have shown that GSK1838705A can effectively treat solid tumors and lymphomas. In one phase I study, researchers found that GSK1838705A was well-tolerated and showed signs of efficacy in patients with advanced solid tumors who had previously received other treatments.
GSK1838705A works by specifically targeting the PI3K pathway, which is often overactive in cancer cells and plays a critical role in regulating cell growth and survival. By inhibiting this pathway, GSK1838705A suppresses the signaling pathways that are critical for cancer cell growth and survival, thereby slowing down or stopping cancer progression.
GSK1838705A has generally been well-tolerated in clinical trials. However, like all medications, it can cause side effects. Common side effects include fatigue, nausea, vomiting, and diarrhea. More severe side effects may occur in some patients, such as liver damage or allergic reactions. Patients should be closely monitored for any adverse reactions while taking GSK1838705A.
The most common side effects of GSK1838705A include:
More severe side effects may occur in some patients, such as:
The dosing of GSK1838705A depends on the type of cancer being treated and other individual factors. It is typically administered orally in tablet form, either alone or in combination with other cancer therapies. The recommended dose varies depending on the clinical trial or physician's discretion.
In conclusion, GSK1838705A is a promising drug candidate for cancer therapy, particularly in the treatment of various types of cancers, including solid tumors and lymphomas. By inhibiting the PI3K pathway, it shows potential in suppressing the signaling pathways that are critical for cancer cell growth and survival, thereby slowing down or stopping cancer progression. While further clinical trials are needed to determine its efficacy and safety, GSK1838705A represents an important step towards precision medicine and molecular targeted therapy in cancer treatment.